{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T03:59:37Z","timestamp":1792209577655,"version":"4.4.0"},"reference-count":16,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"32","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO"],"published-print":{"date-parts":[[2020,11,10]]},"abstract":"<jats:sec>\n                    <jats:title>PURPOSE<\/jats:title>\n                    <jats:p>Low-grade serous ovarian carcinomas (LGSOCs) have historically low chemotherapy responses. Alterations affecting the MAPK pathway, most commonly KRAS\/BRAF, are present in 30%-60% of LGSOCs. The purpose of this study was to evaluate binimetinib, a potent MEK1\/2 inhibitor with demonstrated activity across multiple cancers, in LGSOC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>This was a 2:1 randomized study of binimetinib (45 mg twice daily) versus physician\u2019s choice chemotherapy (PCC). Eligible patients had recurrent measurable LGSOC after \u2265 1 prior platinum-based chemotherapy but \u2264 3 prior chemotherapy lines. The primary end point was progression-free survival (PFS) by blinded independent central review (BICR); additional assessments included overall survival (OS), overall response rate (ORR), duration of response (DOR), clinical-benefit rate, biomarkers, and safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>A total of 303 patients were randomly assigned to an arm of the study at the time of interim analysis (January 20, 2016). Median PFS by BICR was 9.1 months (95% CI, 7.3 to 11.3) for binimetinib and 10.6 months (95% CI, 9.2 to 14.5) for PCC (hazard ratio,1.21; 95%CI, 0.79 to 1.86), resulting in early study closure according to a prespecified futility boundary after 341 patients had enrolled. Secondary efficacy end points were similar in the two groups: ORR 16% (complete response [CR]\/partial responses[PRs], 32) versus 13% (CR\/PRs, 13); median DOR, 8.1 months (range, 0.03 to \u2265 12.0 months) versus 6.7 months (0.03 to \u2265 9.7 months); and median OS, 25.3 versus 20.8 months for binimetinib and PCC, respectively. Safety results were consistent with the known safety profile of binimetinib; the most common grade \u2265 3 event was increased blood creatine kinase level (26%). Post hoc analysis suggests a possible association between KRAS mutation and response to binimetinib. Results from an updated analysis (n = 341; January 2019) were consistent.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>Although the MEK Inhibitor in Low-Grade Serous Ovarian Cancer Study did not meet its primary end point, binimetinib showed activity in LGSOC across the efficacy end points evaluated. A higher response to chemotherapy than expected was observed and KRAS mutation might predict response to binimetinib.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/jco.20.01164","type":"journal-article","created":{"date-parts":[[2020,8,21]],"date-time":"2020-08-21T15:59:24Z","timestamp":1598025564000},"page":"3753-3762","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":140,"title":["MILO\/ENGOT-ov11: Binimetinib Versus Physician\u2019s Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum"],"prefix":"10.1200","volume":"38","author":[{"given":"Bradley J.","family":"Monk","sequence":"first","affiliation":[{"name":"Arizona Oncology (US Oncology Network), University of Arizona College of Medicine, Creighton University School of Medicine, Phoenix, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel N.","family":"Grisham","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, Weill Cornell Medical Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Banerjee","sequence":"additional","affiliation":[{"name":"Royal Marsden National Health Service Foundation Trust and Institute of Cancer Research, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsa","family":"Kalbacher","sequence":"additional","affiliation":[{"name":"Centre Hospitalier R\u00e9gional et Universitaire de Besan\u00e7on, CHRU de Besan\u00e7on, Besan\u00e7on, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansoor Raza","family":"Mirza","sequence":"additional","affiliation":[{"name":"Nordic Society of Gynaecological Oncology and Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Romero","sequence":"additional","affiliation":[{"name":"Servicio de Oncolog\u0131a Medica, Fundacion Instituto Valenciano de Oncolog\u0131a, Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Vuylsteke","sequence":"additional","affiliation":[{"name":"CHU Universit\u00e9 catholique de Louvain Namur, Sainte-Elisabeth, Namur, Belgium"},{"name":"University of Botswana, Gaborone, Botswana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L.","family":"Coleman","sequence":"additional","affiliation":[{"name":"MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Hilpert","sequence":"additional","affiliation":[{"name":"Onkologisches Therapiezentrum am Krankenhaus Jerusalem, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit M.","family":"Oza","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anneke","family":"Westermann","sequence":"additional","affiliation":[{"name":"Dutch Gynaecological Oncology Group, Amsterdam University Medical Centers, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin K.","family":"Oehler","sequence":"additional","affiliation":[{"name":"Department of Gynaecological Oncology, Royal Adelaide Hospital, Adelaide, South Australia 5005, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandro","family":"Pignata","sequence":"additional","affiliation":[{"name":"Istituto Nazionale Tumori Fondazione Pascale IRCCS, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Aghajanian","sequence":"additional","affiliation":[{"name":"Arizona Oncology (US Oncology Network), University of Arizona College of Medicine, Creighton University School of Medicine, Phoenix, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoletta","family":"Colombo","sequence":"additional","affiliation":[{"name":"Dipartimento Medicina e Chirurgia, Universit\u00e0 Milano-Bicocca, Programma Ginecologia Oncologica Istituto Europeo Oncologia, IRCCS, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Drill","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, Weill Cornell Medical Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Cibula","sequence":"additional","affiliation":[{"name":"First Faculty of Medicine, Charles University in Prague and General University Hospital, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen N.","family":"Moore","sequence":"additional","affiliation":[{"name":"Stephenson Cancer Center at The University of Oklahoma Health Sciences Center, Oklahoma City, OK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janna","family":"Christy-Bittel","sequence":"additional","affiliation":[{"name":"Pfizer, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep M.","family":"del Campo","sequence":"additional","affiliation":[{"name":"Vall d'Hebron University Hospital, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina","family":"Berger","sequence":"additional","affiliation":[{"name":"University Clinic for Gynaecology and Obstetrics, Medical University of Innsbruck, Innsbruck 6020, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Marth","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Medical University of Innsbruck, Austrian AGO, Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jalid","family":"Sehouli","sequence":"additional","affiliation":[{"name":"Center for Oncological Surgery, European Competence Center for Ovarian Cancer Campus Virchow Klinikum and Benjamin Franklin Charit\u00e9 Comprehensive Cancer Center\u2009, Medical University of Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"O\u2019Malley","sequence":"additional","affiliation":[{"name":"The Ohio State University Comprehensive Cancer Center \u2013 James Cancer Hospital and Solove Research Institute, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Churruca","sequence":"additional","affiliation":[{"name":"Biodonostia HRI, Osasun Ikerketa Insitutua, Insituto de Investigacion Sanitaria, San Sebasti\u00e1n, Gipuzkoa, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam P.","family":"Boyd","sequence":"additional","affiliation":[{"name":"Pfizer, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnar","family":"Kristensen","sequence":"additional","affiliation":[{"name":"Department for Gynecologic Oncology and Institute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Clamp","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The Christie National Health Service Foundation Trust, and University of Manchester, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Ray-Coquard","sequence":"additional","affiliation":[{"name":"Centre L\u00e9on B\u00e9rard, Netsarc Network, Universit\u00e9 Claude Bernard Lyon 1, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignace","family":"Vergote","sequence":"additional","affiliation":[{"name":"Belgium and Luxemburg Gynaecological Oncology Group, University Hospitals Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq244"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2012.04.029"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27782"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.62.4726"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.5438"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1097\/PAP.0b013e3181b4fffa"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.2353\/ajpath.2010.100212"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1080\/02699050500284218"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2004.12.013"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S1359-6349(10)71867-X"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70572-7"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/IGC.0b013e3181d3caa8"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/j.0006-341X.1999.00874.x"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-1814"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.2339"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2016.12.002"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.20.01164","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,29]],"date-time":"2022-05-29T04:21:38Z","timestamp":1653798098000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.20.01164"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,10]]},"references-count":16,"journal-issue":{"issue":"32","published-print":{"date-parts":[[2020,11,10]]}},"alternative-id":["10.1200\/JCO.20.01164"],"URL":"https:\/\/doi.org\/10.1200\/jco.20.01164","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,10]]},"assertion":[{"value":"2020-06-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}